Clinical Trials Logo

Fibrosis clinical trials

View clinical trials related to Fibrosis.

Filter by:

NCT ID: NCT05304455 Completed - Cirrhosis Clinical Trials

Apixaban Prevents Portal Vein Thrombosis After Laparoscopic Splenectomy and Azygoportal Disconnection

ESAPT
Start date: April 1, 2022
Phase: N/A
Study type: Interventional

The purpose of this study is to determine whether Apixaban is effective and safe in Prevention of Portal Vein Thrombosis in Liver Cirrhotic Patients after Laparoscopic Splenectomy and Azygoportal Disconnection

NCT ID: NCT05300516 Completed - Hypertension Clinical Trials

Vagus Nerve-guided Robotic-assisted Splenectomy and Azygoportal Disconnection

VNRSD
Start date: April 1, 2022
Phase: N/A
Study type: Interventional

This study aimed to evaluate whether vagus nerve-guided robotic-assisted splenectomy and azygoportal disconnection is effective and safe, and to determine whether a reduction in the incidence of postoperative complications of the digestive system improves postoperative quality of life compared with conventional robotic-assisted splenectomy and azygoportal disconnection.

NCT ID: NCT05287100 Completed - Cirrhosis, Liver Clinical Trials

To Assess the Efficacy of Midodrine in Prevention of Cirrhosis Related Complications in Children Awaiting Liver Transplantation.

Start date: January 1, 2022
Phase: N/A
Study type: Interventional

Children with cirrhosis awaiting transplantation are more proned to develop various complications. The pathogenesis of cirrhotic complications (ascites, hyponatremia, acute kidney injury) includes release of vasodilatory molecules like nitric oxide, damage associated molecular pathogens (DAMPs) and pattern associated molecular pathogens (PAMPs) secondary to bacterial translocation, which causes splanchnic bed vasodilation resulting in activation of renin-angiotensin and aldosterone axis(RAAS) causing sodium and water retention and renal vasoconstriction [1]. The development of complications in these children may result in death or may preclude them from reaching upto liver transplantation [2]. Midodrine is an α1 adrenergic receptor agonist, which increases vascular tone causing rise in the blood pressure, thereby improving renal perfusion and causes RAAS deactivation. The effects of midodrine is documented in reduction of refractory ascites, hepatorenal syndrome and hyponatremia[2-4]. One group will receive only standard medical therapy and other group will receive midodrine and standard medical therapy for 6 months. Mean arterial pressure will be monitored at every OPD visit. At the end of 12 weeks, and 24 weeks, plasma renin activity, incidence of complications related to cirrhosis like new onset ascites, increase in grade of ascites, hyponatremia, acute kidney injury and spontaneous bacterial peritonitis will be assessed. Also the transplant free survival and need for albumin transfusion will be compared between the two groups. In case of liver transplantation or death before 6 months, midodrine will be stopped

NCT ID: NCT05285410 Completed - Cystic Fibrosis Clinical Trials

Observational Study Comparing Home to Office Spirometry

OUTREACH
Start date: November 30, 2022
Phase:
Study type: Observational

This is a prospective, longitudinal multicenter observational study comparing home to office spirometry and home to office weight and height measurements. The aim of the study is to estimate the accuracy and variability of home spirometric measurements over time, and to assess the feasibility and acceptability of home measurements.

NCT ID: NCT05274269 Completed - Cystic Fibrosis Clinical Trials

Evaluation of Efficacy and Safety of Elexacaftor/Tezacaftor/Ivacaftor (ELX/TEZ/IVA) in Cystic Fibrosis Subjects Without an F508del Mutation

Start date: May 9, 2022
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy, pharmacodynamics (PD) and safety of ELX/TEZ/IVA in participants 6 years of age and older with a non-F508del ELX/TEZ/IVA-responsive cystic fibrosis transmembrane conductance regulator gene (CFTR) mutation.

NCT ID: NCT05250401 Completed - Liver Cirrhosis Clinical Trials

Thyroid Function in Liver Cirrhosis: Is it Affected?

Start date: May 18, 2021
Phase:
Study type: Observational

In patient with liver cirrhosis ,thyroid functions are largely affected in our study we studied the changes in thyroid functions in patients with liver cirrhosis

NCT ID: NCT05231772 Completed - Cirrhosis Clinical Trials

Probiotics and Hemodynamic Changes in Cirrhosis

PrBHCCir
Start date: March 1, 2021
Phase: N/A
Study type: Interventional

This is a single-center blinded randomized interventional placebo-controlled study of the effect of probiotics on hemodynamic parameters and liver function in cirrhosis.

NCT ID: NCT05225805 Completed - Cystic Fibrosis Clinical Trials

Study to Assess the Safety and PK of Oral and IV Xenleta in Adults With Cystic Fibrosis

Start date: March 1, 2022
Phase: Phase 1
Study type: Interventional

This study is intended to assess the pharmacokinetic (PK) and safety of a single dose of IV and oral formulations of lefamulin in adults with cystic fibrosis (CF).

NCT ID: NCT05224037 Completed - Liver Fibrosis Clinical Trials

Comparative Efficacy of Liver Fibrosis and Steatosis Assessment With Fibroscan and iLivTouch

OGIG-01-22-LF
Start date: January 21, 2022
Phase: N/A
Study type: Interventional

This study is aimed to compare the results and operating characteristics of liver stiffness measurement with the use of Fibroscan (EchoSens, France) and iLivTouch (Wuxi Hisky Medical Technologies Co., China) in patients with chronic liver diseases.

NCT ID: NCT05202457 Completed - Cirrhosis, Liver Clinical Trials

Cirrhotics Undergoing General Surgery

Start date: June 27, 2017
Phase:
Study type: Observational

Surgery on cirrhotic patients represents a clinical challenge but intervening before these patients develop complications can prolong the likelihood of these patients making it to transplant for those transplant-eligible candidates. There is no literature on survival to transplant afforded by surgery nor 90 day and 1-year outcomes after any surgical procedures on this population. The investigator's aim is to study the principal investigator's single surgical center experience at a tertiary hospital with the largest referral center in the area for liver transplant candidates. The investigators hypothesize, that although the risk is high for patients undergoing surgery it is much lower than historically reported, may make more patients eligible for transplant and prevent complications that may lead to death for the transplant eligible, and may reveal associations that can lead to good outcomes in this high-risk population.